Panchkula
08042783888
+919530953095

Seroxim-500 (Cefuroxime 500mg) – PCD Pharma Franchise Opportunity in India

Looking for a high-demand antibiotic product for your PCD pharma franchise portfolio? Seroxim-500 (Cefuroxime Axetil Tablets I.P. 500mg) by Serapher Lifesciences is a trusted broad-spectrum antibiotic widely prescribed for respiratory, ENT, urinary, and skin infections.

We offer monopoly-based PCD pharma franchise opportunities across India with attractive margins and promotional support.

Product Overview – Seroxim-500 Tablets

Brand Name: Seroxim-500

Generic Name: Cefuroxime Axetil Tablets I.P. 500mg

Packing: 10x10 Tablets

Category: Second-generation Cephalosporin Antibiotic

Cefuroxime 500mg is commonly prescribed for:

  • Respiratory tract infections
  • ENT infections
  • Bronchitis and chest infections
  • Urinary tract infections (UTI)
  • Skin and soft tissue infections
  • Bacterial wound infections

Why Choose Seroxim-500 for PCD Pharma Franchise?

✅ High Market Demand

Antibiotics remain one of the fastest-moving segments in the Indian pharma market.

✅ Strong Doctor Acceptance

Cefuroxime 500mg is widely prescribed by physicians, general practitioners, and ENT specialists.

✅ Attractive PCD Margins

We offer competitive rates and high profit margins for franchise partners.

✅ Monopoly Rights

District-wise monopoly-based PCD franchise opportunities available.

✅ Promotional Support

  • Visual Aids
  • MR Bags
  • Product Cards
  • Leave Behind Literature
  • Sample Packs

Benefits of Partnering with Serapher Lifesciences

  • ISO Certified Company
  • Quality Assured Manufacturing
  • Wide Product Portfolio
  • Timely Delivery Across India
  • Transparent Business Policy
  • Dedicated Franchise Support Team

Target Areas for Franchise Expansion

We are actively expanding our PCD pharma franchise network in:

  • Haryana
  • Punjab
  • Himachal Pradesh
  • Rajasthan
  • Bihar
  • Odisha
  • North East States
  • Maharashtra
  • Uttar Pradesh
  • Madhya Pradesh
  • South India States


 2026-03-03T06:35:55

Keywords